Zinc Paste Instructions for Use
ATC Code
D02AB (Zinc preparations)
Active Substance
Zinc oxide (Ph.Eur. European Pharmacopoeia)
Clinical-Pharmacological Group
Drug with astringent and drying action for external use
Pharmacotherapeutic Group
Preparations with emollient and protective action. Zinc preparations
Pharmacological Action
Zinc oxide exerts a drying, adsorbent, astringent, and disinfectant action.
It reduces exudation and weeping, which alleviates local inflammatory phenomena and irritation.
Indications
Diaper rash, intertrigo, miliaria, dermatitis, ulcerative skin lesions, superficial wounds, and burns.
ICD codes
| ICD-10 code | Indication |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L22 | Diaper dermatitis |
| L23 | Allergic contact dermatitis |
| L24 | Irritant contact dermatitis |
| L25 | Unspecified contact dermatitis |
| L30.0 | Nummular eczema |
| L30.4 | Erythematous intertrigo |
| L30.9 | Dermatitis, unspecified |
| L74.3 | Unspecified miliaria |
| L89 | Decubitus ulcer and pressure area |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T30 | Burns and corrosions of unspecified body region |
| ICD-11 code | Indication |
| 9A06.70 | Atopic eczema of the eyelids |
| EA40 | Tropical phagedenic ulcer |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA82 | Nummular dermatitis |
| EA85.20 | Atopic hand eczema |
| EA85.2Z | Hand dermatitis, unspecified |
| EA85.3 | Foot dermatitis |
| EA89 | Generalized eczematous dermatitis of unspecified type |
| EA8Z | Dermatitis or eczema, unspecified |
| EF60 | Ischemic ulceration of the skin |
| EH40.10 | Diaper dermatitis |
| EH90.Z | Pressure ulcer of unspecified degree |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| EK00.Z | Allergic contact dermatitis, unspecified |
| EK02.20 | Intertriginous dermatitis due to friction, sweating or contact with body fluids |
| EK02.Z | Irritant contact dermatitis, unspecified |
| EK5Y | Other specified skin lesions provoked by exposure to external factors |
| EM0Z | Unspecified skin disorder |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| ND56.0 | Superficial injury of unspecified body region |
| NE11 | Burn of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply the paste externally to the affected skin areas.
Administer the paste three to six times daily or as directed by a physician.
Adjust the amount of paste applied according to the size and severity of the lesion.
Apply a thin, uniform layer to completely cover the affected area.
For weeping or exudative lesions, apply the paste more generously to achieve a protective barrier.
Use the paste under an occlusive dressing, gauze bandage, or diaper as required.
Prior to application, ensure the skin is clean and dry.
Gently remove any residual paste and reapply with each dressing change.
For chronic ulcers or pressure sores, apply the paste after proper wound cleansing and debridement.
Discontinue use and consult a physician if irritation, redness, or worsening of the condition occurs.
The duration of therapy is determined by the clinical response and the nature of the skin condition.
Adverse Reactions
Allergic reactions possible skin itching, hyperemia, skin rash.
Contraindications
Hypersensitivity to zinc oxide.
Use in Pregnancy and Lactation
Use during pregnancy and breastfeeding is possible according to indications, in recommended doses.
Pediatric Use
Use in children is possible according to indications, in recommended doses and dosage forms.
Special Precautions
It is not recommended to use zinc oxide preparations in acute purulent-inflammatory diseases.
Avoid contact with the eyes.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
25% paste for external use: 25 g jars, 30 g tubes
Marketing Authorization Holder
Moscow Pharmaceutical Factory CJS (Russia)
Dosage Form
 |
Zinc paste | 25% paste for external use: 25 g jars, 30 g tubes |
Dosage Form, Packaging, and Composition
| Paste for external use 25% | 100 g |
| Zinc oxide | 25 g |
25 g – dark glass jars (1) – paper packs.
25 g – dark glass jars.
30 g – aluminum tubes (1) – paper packs.
25% paste for external use: 20 g, 25 g, 30 g or 40 g tubes 1 pc.; 25 g or 40 g jars 1 pc.
Marketing Authorization Holder
Tver Pharmaceutical Factory, PJSC (Russia)
Dosage Form
|
Zinc paste | 25% paste for external use: 20 g, 25 g, 30 g or 40 g tubes 1 pc.; 25 g or 40 g jars 1 pc. |
Dosage Form, Packaging, and Composition
Paste for external use white or white with a yellowish tint.
| 100 g | |
| Zinc oxide | 25 g |
Excipients : potato starch – 25 g, petrolatum – up to 100 g.
20 g – aluminum tubes (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
40 g – aluminum tubes (1) – cardboard packs.
25 g – dark glass jars (1) – cardboard packs.
40 g – dark glass jars (1) – cardboard packs.
40 g – polyethylene terephthalate jars (1) – cardboard packs.
25% paste for external use: 25 g jars or tubes
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Zinc paste | 25% paste for external use: 25 g jars or tubes |
Dosage Form, Packaging, and Composition
| Paste for external use 25% | 100 g |
| Zinc oxide | 25 g |
25 g – dark glass jars (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
250 mg/1 ml paste for external use: jars or tubes
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
|
Zinc paste | 250 mg/1 ml paste for external use: jars or tubes |
Dosage Form, Packaging, and Composition
| Paste for external use | 1 ml | 1 package |
| Zinc oxide | 250 mg | 25 g |
25 g – dark glass jars (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
25% paste for external use: 15 g, 20 g, 25 g or 30 g jars, 25 g or 30 g tubes
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Zinc paste | 25% paste for external use: 15 g, 20 g, 25 g or 30 g jars, 25 g or 30 g tubes |
Dosage Form, Packaging, and Composition
Paste for external use from white to white with a yellowish tint.
| 100 g | |
| Zinc oxide | 25 g |
Excipients : potato starch – 25 g, petrolatum – 50 g.
15 g – jars – cardboard packs.
20 g – jars – cardboard packs.
25 g – jars – cardboard packs.
30 g – jars – cardboard packs.
25 g – tubes – cardboard packs.
30 g – tubes – cardboard packs.
![Zinc pasta [Paste] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Zinc pasta [Paste] 2")